Loading stock data…
Septerna (SEPN)
$34.75-2.59 (-6.94%)
After Hours$34.75+0.00 (+0.00%)· Last close Jun 29
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Septerna, Inc. in the Healthcare sector is trading at $34.75 with a market capitalization of $1.6B. Wall Street consensus targets $44.89 (9 analysts), implying a +29.2% move over the next 12 months. The stock is currently near its 52-week high of $37.99, remaining 36.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +29.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26.52M↑ | $24.12M↑ | $21.50M↑ | $119,000↓ | $219,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.30M↑ | -$16.02M↓ | -$9.89M↑ | -$28.98M↓ | -$25.91M |
| Net Income | -$8.64M↑ | -$10.74M↓ | $8.17M↑ | -$24.84M↓ | -$21.48M |
Peer Comparison
JNJUNHPFE
Fundamentals
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R P...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.63B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.52%
Volume
Today's trading volume
1.43M
Recent News
Party Time: Brokers Just Made Major Increases To Their Septerna, Inc. (NASDAQ:SEPN) Earnings Forecasts
Septerna, Inc. ( NASDAQ:SEPN ) shareholders will have a reason to smile today, with the analysts making substantial...
Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported And Analysts Are Boosting Their Estimates
Septerna, Inc. ( NASDAQ:SEPN ) defied analyst predictions to release its first-quarter results, which were ahead of...
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +63.04% and +32.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates
Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +54.76% and +22.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How Analyst Upgrade and Conference Spotlight Will Impact Septerna (SEPN) Investors
Septerna, Inc. recently announced that CEO Jeffrey Finer will present the company’s clinical-stage GPCR drug discovery programs at the Bank of America Securities Health Care Conference on May 12, 2026, with a live webcast available on its investor website. A new positive coverage initiation by a well-regarded Stifel analyst, combined with this high-profile conference appearance, underscores growing institutional attention to Septerna’s pipeline story and investor communications. We will now...